MX2022010176A - Moléculas de unión biespecíficas a gd2 y b7h2 y métodos de uso. - Google Patents

Moléculas de unión biespecíficas a gd2 y b7h2 y métodos de uso.

Info

Publication number
MX2022010176A
MX2022010176A MX2022010176A MX2022010176A MX2022010176A MX 2022010176 A MX2022010176 A MX 2022010176A MX 2022010176 A MX2022010176 A MX 2022010176A MX 2022010176 A MX2022010176 A MX 2022010176A MX 2022010176 A MX2022010176 A MX 2022010176A
Authority
MX
Mexico
Prior art keywords
bind
bispecific
methods
binding molecules
antibody
Prior art date
Application number
MX2022010176A
Other languages
English (en)
Inventor
Daniel Justin Gerhardt
Paul Sondel
Original Assignee
Win Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Win Therapeutics Inc filed Critical Win Therapeutics Inc
Publication of MX2022010176A publication Critical patent/MX2022010176A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se divulgan en este documento construcciones de anticuerpos que unen simultáneamente dos antígenos de superficie celular tumoral, GD2 y B7H3. Los brazos monovalentes que se dirigen a GD2 y B7H3 tiene cada uno afinidad baja a moderada para sus respectivos antígenos. Los anticuerpos multiespecíficas divulgados en este documento se unen para dirigirse a células tumorales cuando ambos brazos del anticuerpo se unen a sus antígenos, resultando en alta especificidad del anticuerpo para células tumorales que expresan GD2 y B7H3.
MX2022010176A 2020-02-20 2021-02-20 Moléculas de unión biespecíficas a gd2 y b7h2 y métodos de uso. MX2022010176A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062979245P 2020-02-20 2020-02-20
PCT/US2021/018939 WO2021168379A1 (en) 2020-02-20 2021-02-20 Bispecific gd2 and b7h2 binding molecules and methods of use

Publications (1)

Publication Number Publication Date
MX2022010176A true MX2022010176A (es) 2023-01-16

Family

ID=77391315

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010176A MX2022010176A (es) 2020-02-20 2021-02-20 Moléculas de unión biespecíficas a gd2 y b7h2 y métodos de uso.

Country Status (12)

Country Link
US (1) US20230018670A1 (es)
EP (1) EP4106805A4 (es)
JP (1) JP2023515807A (es)
KR (1) KR20230015880A (es)
CN (1) CN115867309A (es)
AU (1) AU2021224883A1 (es)
BR (1) BR112022016541A2 (es)
CA (1) CA3168444A1 (es)
CO (1) CO2022013406A2 (es)
IL (1) IL295749A (es)
MX (1) MX2022010176A (es)
WO (1) WO2021168379A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116867514A (zh) * 2020-12-10 2023-10-10 英温拉公司 用于异二聚化的正交突变
KR20230145038A (ko) 2021-02-09 2023-10-17 메디링크 테라퓨틱스 (쑤저우) 컴퍼니, 리미티드 생물활성 물질 접합체, 이의 제조방법 및 이의 용도
JP2025516873A (ja) 2022-05-18 2025-05-30 ▲蘇▼州宜▲聯▼生物医▲薬▼有限公司 タンパク質分解剤クラスの生物学的活性化合物を含む抗体薬物複合体及びその調製方法並びに使用
EP4540290A2 (en) * 2022-06-14 2025-04-23 Invenra Inc. Multispecific binding agents that target b7h3 and gd2 and uses thereof
WO2025223455A1 (en) * 2024-04-24 2025-10-30 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-ptk7/b7h3 antibodies and uses thereof
EP4684803A1 (en) 2024-07-25 2026-01-28 CeMM - Forschungszentrum für Molekulare Medizin GmbH Antibody conjugated chemical inducers of degradation of rbm39 and therapeutic uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1218930A1 (zh) * 2013-02-08 2017-03-17 Abbvie Stemcentrx Llc 新型多特异性结构
TWI742423B (zh) * 2014-05-29 2021-10-11 美商宏觀基因股份有限公司 特異性結合多種癌症抗原的三特異性結合分子和其使用方法
KR102617264B1 (ko) * 2016-10-19 2023-12-29 인벤라 인코포레이티드 항체 구조물
US20190336615A1 (en) * 2017-01-27 2019-11-07 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
SG11201909160WA (en) * 2017-04-11 2019-10-30 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
CA3068256A1 (en) * 2017-06-21 2018-12-27 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric antigen receptor targeting cancer cells
WO2019200022A1 (en) * 2018-04-11 2019-10-17 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
KR20230098637A (ko) * 2020-11-04 2023-07-04 페이트 세러퓨틱스, 인코포레이티드 이종성 종양 제어를 위한 조작된 iPSC 및 면역 효과기 세포

Also Published As

Publication number Publication date
IL295749A (en) 2022-10-01
CA3168444A1 (en) 2021-08-26
KR20230015880A (ko) 2023-01-31
WO2021168379A1 (en) 2021-08-26
CO2022013406A2 (es) 2022-12-20
AU2021224883A1 (en) 2022-09-29
JP2023515807A (ja) 2023-04-14
EP4106805A1 (en) 2022-12-28
CN115867309A (zh) 2023-03-28
US20230018670A1 (en) 2023-01-19
BR112022016541A2 (pt) 2022-11-16
EP4106805A4 (en) 2024-07-03

Similar Documents

Publication Publication Date Title
MX2022010176A (es) Moléculas de unión biespecíficas a gd2 y b7h2 y métodos de uso.
WO2022175255A3 (en) Trispecific antibody targeting bcma, gprc5d, and cd3
MX2021009151A (es) Anticuerpos y receptores de antigeno quimerico especificos para ror1.
EA201990781A1 (ru) Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение
PE20210844A1 (es) Contorsbodies 2 + biespecificos
JOP20160154B1 (ar) أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
WO2019229701A3 (en) Binding molecules against bcma and uses thereof
MX2021015888A (es) Fusión de un anticuerpo que se une a cea y 4-1bbl.
MX2018010776A (es) Moleculas de union de antigeno multiespecificas y usos de las mismas.
MY197218A (en) Multispecific antigen-binding molecules and uses thereof
CL2012000980A1 (es) Inmunoglobulina de dominio variable dual que comprende una cadena de polipeptidos con dos dominios variables que se unen a cd3 y a cd19 y; conjugado con la proteina de union; celula huesped, vector y acido nucleico, metodo de produccion, composicion, metodo in vitro que utiliza la proteina y usos para preparar un medicamento.
MX2021006389A (es) Anticuerpo cd3 y uso farmaceutico del mismo.
ZA202210626B (en) Anti-cd137 constructs, multispecific antibody and uses thereof
EP4309740A3 (en) Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
PH12023500005A1 (en) Multi-specific antigen binding molecules targeting hiv and methods of use
MY150246A (en) Alpha 5 - beta 1 antibodies and their uses
MX2023014647A (es) Proteinas de union a nkp46 multiespecificas.
JOP20230230A1 (ar) جسم مضاد ثلاثي النوعية يستهدف CD79b، وCD20، وCD3
JOP20230246A1 (ar) أجسام مضادة لـ cd122 واستخداماتها
MX2023008044A (es) Anticuerpos monoclonales anti-gprc5d y usos de los mismos.
WO2020168231A3 (en) Antibodies that bind tumor tissue, and their diagnostic and therapeutic uses
WO2022108976A3 (en) Anti-gpa33 multi-specific antibodies and uses thereof
WO2022251695A8 (en) Multi-specific antibody constructs against the muc1-c/extracellular domain ( muc1-c/ecd)
MX2024008163A (es) Anticuerpos de afinidad alta de dominio unico y metodos de uso de estos.
WO2022256506A3 (en) Dkk1/hla-a2 binding molecules and methods of their use